Study 14 of 17Tesamorelin literatureThe lancet. HIVTop journal2026
Weight management in people with HIV.
Not reported in abstract.
Where it sits
this study against the rest of the tesamorelin corpus1
Preclinical · this one
4
Observational
0
Open-label
9
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Tesamorelin corpus
BWeight management in people with HIV.The lancet. HIV · 2015 · Not reported in abstract.reviewBDetecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.Drug testing and analysis · 2023 · n=6 · Limit of detection for urine was 13 pg/mL and for serum was 41 pg/mL.HumanBDetecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.Drug testing and analysis · 2026 · Limit of detection of 13 pg/mL in urine and 41 pg/mL in serum.HumanAEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.The Journal of clinical endocrinology and metabolism · 2010 · -24 +/- 41 cm(2) VAT reduction in tesamorelin vs 2 +/- 35 cm(2) in placebo at 26 wk, P < 0.001.HumanDTesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.The Annals of pharmacotherapy · 2012 · Not reported in abstract.reviewATesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.BMJ open · 2026Human